Inventor
HINKLE GREGORY
US95 patents
⚠️ This page may combine multiple inventors who share the name “HINKLE GREGORY”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ALNYLAM PHARMACEUTICALS INC
36 patentsUS10934544B2Mar 2, 2021
Factor XII (hageman factor) (F12), kallikrein B, plasma (fletcher factor) 1 (KLKB1), and kininogen 1 (KNG1) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC15 citations94
US10570393B2Feb 25, 2020
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC17 citations94
US9574192B2Feb 21, 2017
Serapina1 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC14 citations92
US9234196B2Jan 12, 2016
Compositions and methods for inhibiting expression of transthyretin
ALNYLAM PHARMACEUTICALS INC18 citations92
US11198872B2Dec 14, 2021
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC6 citations84
US11142766B2Oct 12, 2021
Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC4 citations84
US11034958B2Jun 15, 2021
Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC7 citations84
US11015201B2May 25, 2021
Angiotensinogen (AGT) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC6 citations84
US10513703B2Dec 24, 2019
Hepatitis B virus (HBV) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC6 citations84
US10407679B2Sep 10, 2019
Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC5 citations84
US10238749B2Mar 26, 2019
Angiotensinogen (AGT) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC12 citations84
US10231988B2Mar 19, 2019
Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC10 citations84
US10030244B2Jul 24, 2018
Serpina1 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC6 citations84
US10240152B2Mar 26, 2019
Compositions and methods for inhibiting expression of transthyretin
ALNYLAM PHARMACEUTICALS INC6 citations83
US10370666B2Aug 6, 2019
Ketohexokinase (KHK) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC5 citations82
US11866701B2Jan 9, 2024
Complement component C3 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC2 citations73
US11834661B2Dec 5, 2023
Angiotensinogen (AGT) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC2 citations73
US11419942B2Aug 23, 2022
Angiotensinogen (AGT) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC2 citations73
US11408001B1Aug 9, 2022
Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC1 citations73
US11060091B2Jul 13, 2021
Hepatitis B virus (HBV) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC2 citations73
US11052103B2Jul 6, 2021
Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC2 citations73
US10982215B2Apr 20, 2021
Polynucleotide agents targeting programmed cell death 1 ligand 1 (PD-L1) and methods of use thereof
ALNYLAM PHARMACEUTICALS INC2 citations73
US10920223B2Feb 16, 2021
Serpina1 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC2 citations73
US10883107B2Jan 5, 2021
Polynucleotide agents targeting factor XII (hageman factor) (F12) and methods of use thereof
ALNYLAM PHARMACEUTICALS INC2 citations73
US10814007B2Oct 27, 2020
Angiotensinogen (AGT) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC3 citations73
US10709728B2Jul 14, 2020
Polynucleotide agents targeting angiotensinogen (AGT) and methods of use thereof
ALNYLAM PHARMACEUTICALS INC6 citations73
US10683504B2Jun 16, 2020
Serpina1 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC2 citations73
US10597661B2Mar 24, 2020
Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (PNPLA3) and methods of use thereof
ALNYLAM PHARMACEUTICALS INC4 citations73
US10472628B2Nov 12, 2019
Lipid formulated compositions and methods for inhibiting expression of Serum Amyloid A gene
ALNYLAM PHARMACEUTICALS INC1 citations73
US10400238B2Sep 3, 2019
Polynucleotide agents targeting complement component C5 and methods of use thereof
ALNYLAM PHARMACEUTICALS INC4 citations73
US10077444B2Sep 18, 2018
Compositions and methods for inhibiting expression of the LECT2 gene
ALNYLAM PHARMACEUTICALS INC2 citations73
US11434487B2Sep 6, 2022
Sterol regulatory element binding protein (SREBP) chaperone (SCAP) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC2 citations72
US10767177B2Sep 8, 2020
Sterol regulatory element binding protein (SREBP) chaperone (SCAP) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC4 citations72
US11136582B2Oct 5, 2021
Ketohexokinase (KHK) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC4 citations71
US12569511B2Mar 10, 2026
Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC0 citations63
US11685918B2Jun 27, 2023
Programmed cell death 1 ligand 1 (PD-L1) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC0 citations63
FITZGERALD KEVIN
3 patentsUS8273869B2Sep 25, 2012
Lipid formulated dsRNA targeting the PCSK9 gene
FITZGERALD KEVIN17 citations92
US8598139B2Dec 3, 2013
Lipid formulated dsRNA targeting the PCSK9 gene
FITZGERALD KEVIN15 citations84
US8765932B2Jul 1, 2014
Compositions and methods for inhibiting expression of XBP-1 gene
FITZGERALD KEVIN4 citations73
SAH DINAH WEN-YEE
2 patentsARROWHEAD RES CORP
2 patentsHINKLE GREGORY
2 patentsDE FOUGEROLLES ANTONIN
1 patentGOLLOB JARED
1 patentARROWHEAD PHARMACEUTICALS INC
1 patentCHEN JINYUN
1 patentREGENERON PHARMA
1 patentShowing the top 50 of 95 patents by PatentIndex Score.